Related Experiment Video
Updated: Jun 23, 2025
A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro
Published on: January 9, 2018
Disrupting Smad3 potentiates immunostimulatory function of NK cells against lung carcinoma by promoting GM-CSF
Guang-Yu Lian1,2,3, Qing-Ming Wang3,4, Thomas Shiu-Kwong Mak3
1Guangdong-Hong Kong Joint Research Laboratory on Immunological and Genetic Kidney Diseases, Departments of Pathology and Nephrology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.
Abstract:
Through Smad3-dependent signalings, transforming growth factor-β (TGF-β) suppresses the development, maturation, cytokine productions and cytolytic functions of NK cells in cancer. Silencing Smad3 remarkably restores the cytotoxicity of NK-92 against cancer in TGF-β-rich microenvironment, but its effects on the immunoregulatory functions of NK cells remain obscure. In this study, we identified Smad3 functioned as a transcriptional repressor for CSF2 (GM-CSF) in NK cells. Therefore, disrupting Smad3 largely mitigated TGF-β-mediated suppression on GM-CSF production by NK cells. Furthermore, silencing GM-CSF in Smad3 knockout NK cells substantially impaired their anti-lung carcinoma effects. In-depth study demonstrated that NK-derived GM-CSF strengthened T cell immune responses by stimulating dendritic cell differentiation and M1 macrophage polarization. Meanwhile, NK-derived GM-CSF promoted the survival of neutrophils, which in turn facilitated the terminal maturation of NK cells, and subsequently boosted NK-cell mediated cytotoxicity against lung carcinoma. Thus, Smad3-silenced NK-92 (NK-92-S3KD) may serve as a promising immunoadjuvant therapy with clinical translational value given its robust cytotoxicity against malignant cells and immunostimulatory functions to reinforce the therapeutic effects of other immunotherapies.
Insights
Silencing Smad3 in NK cells enhances their anti-cancer activity by boosting GM-CSF production. This promotes immune responses and NK cell maturation, offering potential for cancer immunotherapy.
Area of Science:
- Immunology
- Cancer Biology
- Cellular Signaling
Background:
- Transforming growth factor-β (TGF-β) signaling, mediated by Smad3, suppresses Natural Killer (NK) cell functions in cancer.
- While Smad3 silencing restores NK-92 cell cytotoxicity in TGF-β-rich environments, its impact on NK cell immunoregulatory roles is unclear.
Purpose of the Study:
- To investigate the role of Smad3 in regulating Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) production in NK cells.
- To elucidate the mechanisms by which Smad3 impacts NK cell anti-cancer activity and immune regulation.
Main Methods:
- Utilized Smad3 knockout NK-92 cell models.
- Analyzed GM-CSF expression and its downstream effects on immune cells (T cells, dendritic cells, macrophages, neutrophils).
- Assessed the anti-lung carcinoma effects of Smad3-silenced NK cells.
Main Results:
- Identified Smad3 as a transcriptional repressor of GM-CSF in NK cells.
- Smad3 disruption mitigated TGF-β-induced suppression of GM-CSF production.
- NK-derived GM-CSF enhanced T cell responses, promoted M1 macrophage polarization, supported neutrophil survival, and boosted NK cell-mediated anti-lung carcinoma cytotoxicity.
Conclusions:
- Smad3-silenced NK-92 cells (NK-92-S3KD) exhibit enhanced anti-cancer cytotoxicity and immunostimulatory functions.
- NK-derived GM-CSF plays a crucial role in orchestrating innate and adaptive immune responses against lung carcinoma.
- Smad3-silenced NK cells represent a potential immunoadjuvant therapy for cancer, enhancing existing immunotherapies.
More Related Videos
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
